Walsh currently serves as the executive vice president and chief financial officer at Catalent, a role he assumed in 2008. Prior to joining Catalent, he was president, chief financial officer, and acting chief executive officer at Escala Group, Inc.
Walsh is a CFA charterholder who received an MBA from Cornell University, SC Johnson Graduate School of Management, and a BS in Chemical Engineering from Cornell University, College of Engineering.
Allergan is a global pharmaceutical company focused on developing, manufacturing and commercializing branded pharmaceuticals, devices, and biologic products for patients around the world.
The company markets a portfolio of products for the central nervous system, eye care, medical aesthetics and dermatology, gastroenterology, women's health, urology and anti-infective therapeutic categories.
GelMEDIX completes USD13m seed financing, announces first partnership
AmacaThera named Life Sciences Ontario Emerging Company of the Year
GenSight Biologics reports first patient treated in GS010 REVISE study
Biophytis secures Asian partnership and investment to advance Phase 3 sarcopenia programme
MemorialCare hospitals recognised in 2026 Women's Choice Awards
Champions Oncology expands bioanalytical services with new technology and leadership
PhaseV receives three industry honours for AI in clinical development
Galapagos plans to wind down cell therapy business following strategic review
Sebela's MIUDELLA Hormone-Free Copper IUS recognised in TIME's best inventions of 2025
Revelation Pharma acquires Acacia Apothecary & Wellness
Viatris receives fifth consecutive recognition on Forbes' annual list of World's Best Employers